Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is having an incredible day in the market today after announcing that a clinical hold with regard to one of its candidates had been lifted. As you could imagine, this overwhelmingly positive news is exciting to say the least and investors are reacting. Today, we’ll talk about:
- The lift of the clinical hold;
- what we’re seeing from the stock as a result;
- and what we’ll be watching for with regard to BLCM ahead.
FDA Lifts Clinical Hold On BLCM Candidate
As mentioned above, Bellicum Pharmaceuticals is having a strong day in the market today after announcing that the FDA has lifted a clinical hold on one of its treatment candidates. In a press release issued late yesterday, the company announced that the United States Food and Drug Administration has lifted the clinical hold on studies surrounding BPX-501 in the United States.
In the release, BLCM said that the decision is the result of consultation with the FDA and agreement to amend the study protocols. Moving forward, study protocols will include the FDA’s guidance on monitoring and management of neurologic adverse events. the company said that it intends to work with U.S. clinical sites to resume patient recruitment based on the amended protocols.
BLCM also said that the FDA clinical hold had no affect on the BP-004 registrational trial in Europe. The company said that this trial is fully enrolled.
What We’re Seeing From The Stock
With the positive news that the FDA has lifted the clinical hold surrounding Bellicum Pharmaceuticals’ BPX-501, it’s no surprise to see that excited investors are sending this stock skyward today. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:01), BLCM is trading at $8.03 per share after a gain of $1.18 per share or 17.21% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on BLCM. In particular, we’re interested in in the ongoing development efforts surrounding both BPX-501 and BP-004. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks.
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!